

# NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

## **Nerviano Medical Sciences S.r.l. announced new Board of Directors and Statutory Auditors**

**NERVIANO, 28, May 2024**\_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company itself and of all its subsidiaries due to termination of mandates. This transition is part of our ongoing commitment to strong corporate governance and effective leadership.

### **Nerviano Medical Sciences S.r.l.**

#### Changes to the Board of Directors

We would like to inform you of the following appointments to our Board of Directors:

- Hugues Dolgos (Chairman and CEO)
- Lisa Mahnke
- Sidney Dung
- Serena Alvino
- Tiziano Lazzaretti

These appointments follow the conclusion of the mandates of the following directors:

- Hugues Dolgos (Chairman and CEO)
- Lisa Mahnke

#### Changes to Statutory Auditors

Additionally, we are pleased to announce the appointment of new statutory auditors:

- Andrea Piermartini Rosi (Chairman)
- Annalisa De Palma
- Massimo Gabelli

These appointments follow the conclusion of the mandates of the following auditors:

- Mario Tagliaferri (Chairman)
- Stefano Sacchi
- Massimo Venuti

We extend our sincere gratitude to the outgoing directors and auditors for their dedicated service and valuable contributions to NMS Group and its subsidiaries. We welcome the new members and are confident that their expertise will significantly benefit the company.

# NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

*Read more: about the Board of Directors and Statutory Auditors of all **NMS Group** companies please click the link below:*

<https://www.nmsgroup.it/governance-and-ethics-compliance/>

###

## **About Nerviano Medical Sciences**

[Nerviano Medical Sciences](#) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

## **About NMS Group**

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

**Media Relations:** [sidney.dung@nervianoms.com](mailto:sidney.dung@nervianoms.com)